Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

KEYNOTE022: Triplet therapy for BRAF melanoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 22.10.18
Views: 640
Rating:

Prof Paolo Ascierto - Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Milan, Italy

Prof Paolo Ascierto speaks with ecancer at ESMO 2018 in Munich about results from a phase 2 randomised study of dabrafenib and trametinib plus PD-L1 checkpoint therapy pembrolizumab for BRAFm advanced melanoma.

Prof Ascierto discusses how immuno-oncology is adding to melanoma treatment, with the dabrafenib trametinib combination already found effective in the adjuvant setting through the COMBI-AD trial.

The results, including the improved CR rate of 18% v 13% and median duration of response of 18.7mo v 12.5mo must be weighed against the increased toxicity profile, with 40% of patients discontinuing from the triplet therapy due to adverse events.

These results are also featured in the ESMO Melanoma round-up.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Breast Cancer CDK 4/6


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation